Fmr LLC lowered its holdings in Denali Therapeutics Inc (NASDAQ:DNLI) by 4.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,711,049 shares of the company’s stock after selling 325,977 shares during the period. Fmr LLC owned about 8.13% of Denali Therapeutics worth $167,638,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also added to or reduced their stakes in the company. Osborn Williams & Donohoe LLC bought a new position in shares of Denali Therapeutics in the 3rd quarter valued at about $217,000. Trexquant Investment LP bought a new position in shares of Denali Therapeutics in the 2nd quarter valued at about $155,000. JPMorgan Chase & Co. grew its position in shares of Denali Therapeutics by 207.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,554 shares of the company’s stock valued at $229,000 after acquiring an additional 7,120 shares during the period. UBS Group AG grew its position in shares of Denali Therapeutics by 5,364.5% in the 1st quarter. UBS Group AG now owns 10,929 shares of the company’s stock valued at $215,000 after acquiring an additional 10,729 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Denali Therapeutics in the 2nd quarter valued at about $207,000. 70.52% of the stock is owned by institutional investors and hedge funds.
NASDAQ DNLI opened at $19.57 on Friday. The stock has a market cap of $1.68 billion and a PE ratio of -3.32. Denali Therapeutics Inc has a 52-week low of $12.32 and a 52-week high of $25.79.
Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, November 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.13). The firm had revenue of $1.20 million for the quarter, compared to the consensus estimate of $3.00 million. Research analysts forecast that Denali Therapeutics Inc will post -1.37 earnings per share for the current year.
A number of brokerages have recently commented on DNLI. Cantor Fitzgerald set a $25.00 price objective on shares of Denali Therapeutics and gave the company a “buy” rating in a research report on Friday. Janney Montgomery Scott began coverage on shares of Denali Therapeutics in a research report on Monday, November 12th. They issued a “buy” rating and a $26.00 price objective for the company. Finally, Zacks Investment Research downgraded shares of Denali Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 14th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. Denali Therapeutics presently has a consensus rating of “Buy” and an average price target of $24.00.
In other news, insider Ryan J. Watts sold 18,334 shares of the firm’s stock in a transaction dated Thursday, November 15th. The shares were sold at an average price of $18.09, for a total transaction of $331,662.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ryan J. Watts sold 18,333 shares of the firm’s stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $18.43, for a total transaction of $337,877.19. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 54,167 shares of company stock valued at $1,049,639. 21.30% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Fmr LLC Has $167.64 Million Position in Denali Therapeutics Inc (DNLI)” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/12/08/fmr-llc-has-167-64-million-position-in-denali-therapeutics-inc-dnli.html.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Further Reading: Yield Curve
Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc (NASDAQ:DNLI).
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.